Xtl Biopharmaceuticals (XTLB) Total Debt (2010 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Total Debt of $138000.0 for Q4 2025, little changed year-on-year from $138000.0 in Q4 2024, and little changed on a QoQ basis from $138000.0 in Q4 2024.
Xtl Biopharmaceuticals (XTLB) Total Debt (2010 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Total Debt for 5 consecutive years, with $138000.0 the latest figure, recorded in Q4 2025.
- Quarterly Total Debt changed 0.0% year-over-year to $138000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $138000.0, changed 0.0% from the prior year.
- Total Debt steadied at $138000.0 in Q4 2025 per XTLB's latest filing, from $138000.0 in the prior quarter.
- Over the last five years, Total Debt for XTLB reached as high as $138000.0 in Q4 2024 and fell as low as $138000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 959.06 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | 138,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Dec 31, 2017 | 2.67 Mn |
| Dec 31, 2011 | 4.07 Bn |
| Dec 31, 2010 | 3.80 Bn |